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ABSTRACT 
L-Asparaginase (L-ASN) is a clinically approved chemotherapeutic agent for the treatment of acute lymphoblastic leukaemia and 
lymphosarcoma. The aim of this research study was to develop and to optimize solid lipid nanoparticle formulation loaded with enzyme L-
Asparaginase using response surface methodology (RSM) [1]. The formulation was prepared by a modified double emulsion method followed by 
solvent evaporation technique using a combination of high-speed homogeniser (10000 rpm) and an automatic hotplate for a temperature 40°C.  
Box-Behnken Design (BBD) was involved in the study to establish and to understand the relationship between selected design factors and the 
experimental data thus obtained. A set of 29 formulations were prepared in triplicate based on the recommendations of BBD. [2] The desired 
results obtained were found to be in close agreement with the experimental results. The responses were ﬁtted to a quadratic; polynomial 
model. The statistical validation using Analysis of Variance (ANOVA) was done for the respective fitted models. [3] Response Surface Graphs and 
3D contour plots were constructed to understand the effect of independent variables in different combinations on the desired responses. SLN 
prepared were found to be spherical in shape and the mean particle size ˂198 nm.[4] The polydispersity index (PDI) and the zeta potential 
recorded for the prepared formulation corresponding to the particle size was 0.096 ± 0.043 and −10.39 mV respectively. The enzyme drug 
loading was 10.11% ± 2.02 and the enzyme entrapment efficiency was found to be 76.19% ± 1.23. BBD found to be very effective in considering 
the effects of independent formulation variables to develop an optimised enzyme loaded SLN formulation with sufficient activi ty of the L-ASN 
enzyme.  
Keywords: Solid Lipid Nanoparticle, Response Surface Methodology, Box-Behnken Design  
 
Article Info: Received 20 April 2019;     Review Completed 30 May 2019;     Accepted 02 June 2019;     Available online 15 June 2019 
Cite this article as: 
Sharma G, Goyal AK, Singh AP, Application of Design Of Expert for the Development and Systematic Optimisation of L-
Asparaginase loaded Nanoparticulate Carrier Drug Delivery Systems, Journal of Drug Delivery and Therapeutics. 2019; 
9(3-s):303-308    http://dx.doi.org/10.22270/jddt.v9i3-s.3017                                                                   
*Address for Correspondence:  
Gazal Sharma, Research Scholar, IKG Punjab Technical University, Kapurthala, Punjab India  
 
 
1.0 INTRODUCTION  
Chemically, L-ASN is a tetrameric protein known to produce 
selective cytotoxic effect on the cancer cells. The cytotoxicity 
is produced through a hydrolytic reaction catalysed by the 
enzyme L-Asparaginase. L-Asparaginase is not found in the 
human blood but it breaks down the essential amino acid L-
Asparagine into L-aspartic acid along with the release of 
ammonia when administered through intravenous route.[5] 
Unlike normal cells, leukemic cells do not have asparagine 
synthetase enzyme for the auto synthesis and subsequent 
replenishment of L-asparagine in cancer cells which leads to 
its apoptosis. This difference in cellular pathway was 
scientifically explored to bring selective cytotoxicity of 
leukemic cells and a breakthrough in the treatment of acute 
lymphocytic leukaemia (ALL). The enzyme L-Asparaginase 
was extracted and found effective against ALL for the first 
time in the year 1953. A chemist J.G. Kidd successfully 
extracted it from the serum of guinea pig and explore its 
hydrolytic characteristics [6]. Since then, it has been used to 
expand life expectancy of leukemic patients. The 
development of a new anti-cancer drug molecule is a very 
lengthy and costly venture so working on the betterment 
and safety efficacy of an existing drug molecule like L-
Asparaginase is comparatively a better alternate move. 
Greater discoveries in the field of drug delivery are also 
projected in the immediate future. The clinical practice of 
drug delivery has reformed vividly with the time. Drug 
Delivery System is an engineered technology, preferably 
used to get sustained release (control the rate at which a 
drug is released) and a better targeted delivery (location in 
the body where it is released) of the anti-cancer drug 
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molecule in the body [7-9]. Next to it is the Carrier Based Drug 
Delivery System (CBDDS). It is a vast research in the field of 
medical science that explores new approaches of controlled 
and sustained drug delivery that commits maximum 
therapeutic effect with minimum side effects [10]. There are 
various forms of carrier-based delivery system which are 
already been explored in the different pharmaceutical labs. 
This includes nanoparticles, solid lipid nanoparticles, 
liposomes, microemulsions, phytosomes etc. This strategy of 
optimization also overlooks interface between factors and 
leads to many experimental runs [11]. Through these studies 
it is made clear that the choice of lipids and surfactants and 
their process parameters like processing speed time and 
temperature brought impact on the desired quality of 
SLN.[12] The desired optimal characteristics of SLN is 
dependent on the relative amount of lipid/oil, surfactant/s, 
the ratio of lipid:drugs etc. This states that the ingredients 
used in the optimised design of SLN significantly affect the 
physicochemical properties like mean particle size, zeta 
potential, PDI and drug-release profiles of the 
nanoparticles.[13] To develop a desired pharmaceutical 
formulation the application of statistical experimental 
design found to be efficient in acquiring the requisite 
information that would help in recognizing the relationship 
between dependent and independent variables. RSM is 
appropriate in doing parallel analysis of formulation 
variables in spite of enormous complexities.[14] Several 
experimental designs[15-17] are used to develop a 
pharmaceutical formulation that provides an estimate of the 
relative significance of different process variables and 
generally requires minimal experimentation. In this study an 
already established and marketed anticancer drug L-
Asparaginase has been transformed into a new formulation 
through using SLN as carrier system (L-ASN loaded SLN).  An 
RSM design Box-Behnken which requires 3-factor 
experimental design was applied to make the study more 
effective.[18] The objective of the study was to evaluate the 
effect of interactions of the process variables through Box-
Behnken design and to further optimize the L-Asparaginase-
loaded SLN formulation. Glyceryl monostearate (GMS) was 
selected as a source of solid lipid and Span 20 and Tween 20 
were taken as emulsifying agents.[19-20] The model drug in 
this study was L-Asparaginase which was encapsulated in 
the SLN. L-ASN loaded SLN was prepared using double 
emulsion method and was further investigated in detail for 
its physicochemical characteristics. The design was 
fabricated using a pool of both independent as well as 
dependent factors. Lipid (X1), Drug conc. (X2), Surfactants 
(X3) and Homogenisation Speed (X4) were selected as the 
independent factors of the design whereas Size of the 
particle (nm) (Y1), Drug Entrapment Efficiency (%) (Y2) and 
Enzyme Loading (%) (Y3) were the chosen as dependent 
variables. BBD found to be very effective in considering the 
effects of independent formulation variables to develop an 
optimised L-ASN loaded SLN formulation consisting of GMS 
(Lipid); Surfactants (Tween 20 and Span 20 used in 2:1 
ratio) and L-Asparaginase (Drug) primarily prepared using 
double emulsion method at a speed 10000 rpm and at a 
constant temperature 40°C and a sufficient activity of the 
enzyme was found in the formulation. 
2.0 MATERIAL AND METHODS 
The standard drug L-Asparaginase in the lyophilised powder 
form was a kind gift received from United Biotech (P) Ltd. 
(India). Glyceryl Monosterate, Span 20 and Tween 20 were 
purchased from Himedia Laboratories (P) Ltd. (India). High-
performance liquid chromatography (HPLC) grade acetone 
was used. Other solvents and reagents were of analytical 
reagent grade purchased from Himedia Laboratories (P) Ltd. 
(India). Homogeniser (Silent Crusher M, Heidolph 
Instruments, Germany) and Magnetic stirrer with hot plate 
(MR Hei-Tec, Heidoph Instruments, Germany) were used for 
the homogenisation, stirring and maintaining 40°C 
temperature during the entire formulation process 
2.1 Preparation of L-Asparaginase loaded SLN and 
determination of Mean Particle Size and Zeta Potential 
L-Asparaginase loaded solid lipid nanoparticles were 
prepared by already reported double emulsion method 
(w/o/w) with some modifications followed by solvent 
evaporation. At first a specific amount of GMS was melted at 
70°C in the presence of acetone used as a solvent in a 
completely covered beaker followed by the addition of Span 
20. The temperature was gradually lower down and 
maintained at 40°C. [18] The standard L-Asparaginase was 
dissolved in deionised sterile water (1mg/1ml) and was 
brought to a temperature of 40°C. The drug solution was 
added at a constantly slower pace into the melted lipid while 
homogenising at a speed of 10000 rpm using high speed 
homogeniser (Silent Crusher M, Heidolph Instruments, 
Germany) for 10 minutes and at a constant temperature to 
prepare the stable primary emulsion. The primary emulsion 
w/o thus prepared was added drop wise into deionised 
sterile water at 40°C which was already having dissolved 
tween 20 and was kept under continuous magnetic stirring 
(MR Hei-Tec, Heidoph Instruments, Germany) at a speed of 
1400 rpm for rapid and complete solvent evaporation.[19] 
The magnetic agitation at a constant temperature was 
continued till a uniform dispersion of nanoparticles as 
w/o/w is obtained. The mean particle size and zeta potential 
of optimised L-Asparaginase loaded SLN formulation were 
measured by Zetasizer (Delsa™Nano Zeta Potential and 
Submicron Particle Size Analyzer by Beckman Coulter). A 
suitable concentration was achieved using deionised water 
before taking the readings of particle size and zeta 
potential[20].   
2.2 Design of Experiment used for formulation 
development  
A Box-Behnken design (29-run, 4-factor, 3-level) was 
applied in the study of the formulation optimization process. 
Polynomial models were constructed using Design-Expert 
software (Trial Version 11.1.2.0, Stat-Ease Inc., MN) in the 
formulation optimisation process. The quadratic response 
surface was suitably investigated with this design. Second 
order polynomial model was constructed with this design. 
The design identifies the main aspects of the study that was 
used to evaluate the major effects, quadratic effects and 
effects of several interactions of the formulation ingredients 
to optimize the formulation process. This design has 
generated the non-linear quadratic model as:  
Y = A0 + A1X1 + A2X2 + A3X3 + A4X4+ A5X1X2 + A6X2X3 + A7X3X4 
+ A8X1X3 + A9X1X4+ A10X2X4+ A11X12+ A12X22+ A13X32+ A14X42 
Y is the measured response of the amount of the Lipid used, 
Drug conc., Surfactants % and Homogenisation Speed 
(dependent variables) associated with each factor-level 
combination; The regression coefficients of the respective 
variables was A0-A1. Their interaction factors were 
computed from the experimental values thus observed as Y; 
and independent variables were coded as X1, X2, X3 and X4. 
The independent factors evaluated in this study for their 03 
values viz low, middle, and high values (−1, 0 and +1), as 
described in Table 1. The dependent responses were studies 
as Y1, Y2, Y3 for the Mean Particle Size, entrapment efficiency 
(EE%) (Y2), drug loading (DL%) (Y3) with constraints 
applied as mentioned in Table 1. The design matrix 
generated by the software shown in Table 2. 
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Table 1: Variables and Levels in the Box-Behnken Design 
 Levels 
-1 0 +1 
Independent Variables 
X1 = Amount of lipid (mg) 225 275 325 
X2 = Amount of Drug (ml) 1 2 3 
X3= Surfactant (%) 4 6 8 
X4= Homogenisation Speed 6000 10000 14000 
 
Dependent Variables 
Y1= Mean Particle Size 
Y2= Entrapment Efficiency (%) 
Y3= Drug Loading (%) 
Constraints 
Minimum 
Maximum 
Maximum 
 
Table 2: Box-Behnken Design 
Formulation Lipid conc. (mg) Surfactant Conc. 
(%) 
Drug Conc. 
(ml) 
Homogenisation Speed 
(rpm) 
1.  225 6 1 10000 
2.  325 4 2 10000 
3.  275 4 2 6000 
4.  275 8 2 14000 
5.  325 6 2 6000 
6.  225 4 2 10000 
7.  325 6 1 10000 
8.  275 4 2 14000 
9.  275 6 2 10000 
10.  275 6 1 6000 
11.  275 6 1 14000 
12.  225 6 2 6000 
13.  275 6 3 6000 
14.  325 8 2 10000 
15.  225 6 3 10000 
16.  275 6 2 10000 
17.  225 6 2 14000 
18.  325 6 2 14000 
19.  275 8 1 10000 
20.  275 8 3 10000 
21.  275 6 2 10000 
22.  275 6 2 10000 
23.  275 8 2 6000 
24.  275 6 3 14000 
25.  275 4 3 10000 
26.  275 6 2 10000 
27.  225 8 2 10000 
28.  275 4 1 10000 
29.  325 6 3 10000 
 
2.3 Determination of Entrapment Efficiency and Drug 
Loading  
The activity of L-Asparaginase was confirmed by in vitro 
Nesslerization method estimated analytically using UV 
visible spectrophotometer (Perkin Elmer). To further 
estimate the percentage drug loading and percentage 
entrapment efficiency the formulation was pellet out using 
centrifugation at 15000 rpm using refrigerated 
centrifugation (Thermo Fischer) at 4°C for 20 min. The pellet 
was further treated with PEG 400 at 40°C. The treated 
formulation dispersed in 35 mL buffer (phosphate buffered 
saline at pH 7.4), to solubilise the drug absorbed on the 
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surface of nanoparticles followed by centrifugation. The free 
drug content in was labelled as Wfree. The % of drug 
encapsulation (EE) and % drug loading were calculated as 
per the equation equations (1) and (2) 
  
       
   
      
Where Wtotal is the weight of total drug added, Wlipid were the 
weight of lipid added in the formulation.  
3.0 RESULTS AND DISCUSSION  
3.1 Analysis of the experimental data using DOE 
Design-Expert software was used to statistically analyse the 
results of formulation parameters engaged in the 
experimental design. The independent variables that 
includes the quantity of lipid used, concentration of 
surfactants added, concentration of drug taken and 
homogenisation speed, reflects its significance in the the 
experimental outcomes as Entrapment Efficiency (%), Drug 
Loading (%) and Particle size (nm) as mentioned in Table 3. 
Based on the estimation of statistical parameters generated 
using Design-Expert software a polynomial equation was 
determined. The equations were validated established using 
statistical tool ANOVA. 3-D model graphs plotted for 
response surface measurement illustrating the effects of the 
factors on the % entrapment efficiency, and Particle size 
(nm) and % drug loading as presented in figures. Using RSM 
plots the effect of interactions between independent 
variables and dependent variables were studied and an 
qualitative effect was found for each variable. This analysis 
done using plots of DoE when observed carefully genuinely 
confirms the qualitative effect of each variable on each 
response which confirmed the its effectiveness in the 
experiments.
 
Table 3: Observed and predicted value of Particle Size (nm), % encapsulation efficiency and %drug loading of formulations 
using design 
Formulation Entrapment Efficiency (%) Drug Loading 
(%) 
Predicted Observed Predicted Observed 
1.  49.52 48.60 68.12 68.22 
2.  65.66 67.40 79.59 80.50 
3.  50.20 50.30 78.30 78.44 
4.  72.87 72.80 84.11 84.04 
5.  76.11 76.30 82.54 82.37 
6.  42.28 49.80 78.85 81.49 
7.  74.55 74.50 69.32 69.50 
8.  49.98 49.80 78.28 78.29 
9.  67.12 66.70 82.91 82.84 
10.  59.64 62.70 68.03 69.40 
11.  56.68 61.60 67.56 69.03 
12.  47.03 42.30 80.68 78.87 
13.  61.14 62.30 86.71 87.12 
14.  87.84 86.40 84.86 84.10 
15.  56.12 56.20 88.27 88.16 
16.  67.12 65.40 82.91 82.53 
17.  53.21 46.90 82.33 80.55 
18.  73.29 71.90 81.64 81.50 
19.  72.18 70.20 72.42 71.74 
20.  75.38 74.30 88.41 88.90 
21.  67.12 69.80 82.91 83.50 
22.  67.12 68.90 82.91 83.28 
23.  69.28 69.50 83.34 83.40 
24.  67.48 70.50 87.93 88.44 
25.  57.34 53.20 86.51 85.24 
26.  67.12 64.80 82.91 82.42 
27.  62.06 66.40 84.45 85.42 
28.  48.24 43.20 63.44 61.00 
29.  80.25 81.20 88.23 88.20 
 
3.2 Effects on Entrapment efficiency (%) The entrapment 
efficiency estimated (%) as mentioned in Table 3 varies from 
42.3% to 84.64% for formulation 12 and formulation 14 
respectively. The independent factors specifically the 
amount of lipid and surfactants affecting the entrapment 
efficiency and this effect can be explained by the following 
quadratic regression equation:  
Y2 = 67.12 + 12.29X1 + 3.07 X2 + 10.49 X3 + 0.8417X4 – 
0.2250X1 X2 +0.6000 X1 X3 - 2.25 X1X4 -1.48X2 X3 + 2.33X2 X4 
+ 0.9500X3 X4 - 0.4183 X12 -1.59X22 -2.24 X32 - 4.29 X42 
The negative value before a factor in the quadratic equation 
depicted that the response decreases with the factor and 
positive value indicates increase in response. The value of 
the correlation coefficient (r2) indicates a good fit as its value 
was found to be 0.9307. The result showed that with the 
increase in the quantity of lipid entrapment efficiency 
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increased gradually. The surfactant also has an important 
positive effect on the entrapment efficiency. Homogenisation 
speed doesn’t produce positive effect on the entrapment 
efficiency. The results are predicted as 3D surface as Figure 
1.  
3.3 Effects on drug loading (%) The drug loading 
estimated (%) as mentioned in Table 3 varies from 61% to 
88.90% for formulation 20 and formulation 28 respectively. 
The independent factors specifically the amount of lipid and 
surfactants affecting the drug loading and this effect can be 
explained by the following quadratic regression equation:  
Y2 = 82.91+0.2883X1+9.76X2 + 2.72X3 +0.1875X4 – 
0.3100X1X2 - 0.0825X1X3- 0.6375X1X4 -1.77X2X3 + 0.4225X2X4 
+ 0.1975X3X4 - 0.0937X12 -4.33X22 -1.02X32 -0.8837X42 
The negative value before a factor in the quadratic equation 
depicted that the response decreases with the factor and 
positive value indicates increase in response. The value of 
the correlation coefficient (r2) indicates a good fit as its value 
was found to be 0.9790. The result showed that with the 
increase in the quantity of drug and homogenisation speed 
drug loading increased gradually. The positive effect of 
increased surfactant conc. and homogenisation speed on the 
drug loading was observed. Lipid conc doesn’t produce 
positive effect on the drug loading. The results are predicted 
as 3D surface as Figure 2.  
4.0 DISCUSSION  
SLN formulation optimisation is multifactorial complex 
research process. It involves many dependent variables and 
independent responses were studied. A complexity of 
interactions was observed. Conclusively this study 
demonstrates that the lipid 275 mg, Drug volume (2ml), 
Surfactants (6%) and Homogenisation speed 10,000 rpm 
were found to be the ingredients of an optimised 
formulation as per the Box-Behnken design. The response 
surface plots and polynomial equations thus obtained, 
predicted an optimised formulation with desired 
characteristics. The L-Asparaginase-SLN obtained in vitro 
release experiments exhibited a biphasic release pattern 
with burst release at the initial phase followed by sustained 
release. 
 
 
Figure 1: Response surface plot showing effect of the different variables on entrapment efficiency 
 
Figure 2: Response surface plot showing effect of the different variables on drug loading 
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